Loading of Human Car T-Cells with Superparamagnetic Iron-Based Particles for Magnetic Targeting

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method for loading human CAR T-cells (genetically engineered T cells used in cancer therapy) with superparamagnetic iron-based particles. These 'magnetized' CAR T-cells can be directed to tumor sites in the body using external magnetic fields. A key feature of these loaded CAR T-cells is their ability to maintain their tumor-killing function while releasing significantly less inflammatory cytokines, potentially reducing dangerous side effects such as cytokine release syndrome. Additionally, because they contain iron-based particles, the location of these cells within the body can be tracked using MRI.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted immunotherapy for solid tumors like melanoma, glioma, sarcoma, and others, by directing CAR T-cells specifically to the tumor site using magnets.
• Reducing systemic side effects (like cytokine release syndrome) during CAR T-cell therapy while maintaining anti-tumor efficacy.
• Real-time monitoring of CAR T-cell distribution and activity within the body using MRI during and after treatment (theranostics).
• Personalized cancer treatment through adjusted dosing and tracking of CAR T-cell persistence based on MRI imaging data.
• Veterinary cancer therapy utilizing magnetically targetable and safer CAR T-cells.
• Basic or translational research involving cell movement/tracking, chemotaxis, and cell-targeted delivery mechanisms using magnetizable cells.

BenefitsContent extracted from patent full text and abstract with AI.

• Reduced risk of severe inflammatory responses (e.g., cytokine storm) by lowering cytokine release from CAR T-cells while maintaining their tumor-killing ability.
• Enhanced safety profile for CAR T-cell therapy, especially for solid tumor patients who traditionally have higher rates of off-target toxicity.
• Ability to physically guide therapeutic T-cells directly to tumor sites using magnetic fields, which can improve treatment specificity and efficacy.
• MRI-based tracking gives clinicians a non-invasive method to confirm that therapeutic cells reach and persist at the tumor, enabling image-guided therapy and real-time intervention if needed.
• Potential for higher doses or repeat administration because of improved control and safety.
• Applicable to a wide range of solid and hematological cancers due to the compatibility with various tumor antigens.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The application describes a T-cell expressing a chimeric antigen receptor ('CAR T-cell') containing superparamagnetic iron-based particles (loaded CAR T-cell') for use in treating a tumor. Said loaded CAR T-cell exhibits a reduced cytokine release upon binding to a cell of the tumor expressing an antigen being recognized by the CAR of the CAR T-cell, compared to a CAR T-cell not containing superparamagnetic iron-based particles ('unloaded CAR T-cell') under the same conditions. Furthermore, an in vitro method of generating a CAR T-cell containing superparamagnetic iron-based particles is described, whereby such loaded CAR T-cells are generated.